ArticleLeukemia2016

Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.

M S Zabriskie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.